Q2 Earnings Forecast for AnaptysBio Issued By HC Wainwright

AnaptysBio, Inc. (NASDAQ:ANAB) – Analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for AnaptysBio in a research report issued to clients and investors on Wednesday, June 10th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings of ($0.84) per share for the quarter. HC Wainwright has a “Buy” rating and a $95.00 price objective on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for AnaptysBio’s Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at $0.10 EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at $2.86 EPS, FY2028 earnings at $5.42 EPS, FY2029 earnings at $6.20 EPS and FY2030 earnings at $7.64 EPS.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($1.20). AnaptysBio had a negative net margin of 11.53% and a negative return on equity of 1,101.24%. The company had revenue of $25.56 million during the quarter, compared to analysts’ expectations of $18.86 million.

A number of other brokerages have also weighed in on ANAB. Piper Sandler dropped their price target on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. UBS Group boosted their price target on AnaptysBio from $60.00 to $76.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Weiss Ratings lowered AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Wedbush boosted their price target on AnaptysBio from $60.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, March 12th. Finally, Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $81.82.

AnaptysBio Price Performance

ANAB opened at $54.24 on Friday. The business’s 50-day moving average is $60.35 and its two-hundred day moving average is $54.40. AnaptysBio has a 1 year low of $11.40 and a 1 year high of $72.36. The firm has a market capitalization of $1.58 billion, a PE ratio of -50.22 and a beta of 0.72.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in AnaptysBio by 4.5% in the fourth quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock valued at $74,855,000 after acquiring an additional 67,048 shares during the period. Granahan Investment Management LLC lifted its holdings in AnaptysBio by 12.2% in the third quarter. Granahan Investment Management LLC now owns 147,773 shares of the biotechnology company’s stock valued at $4,525,000 after acquiring an additional 16,118 shares during the period. Skandinaviska Enskilda Banken AB publ lifted its holdings in AnaptysBio by 333.1% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 145,191 shares of the biotechnology company’s stock valued at $4,446,000 after acquiring an additional 111,668 shares during the period. Tema Etfs LLC lifted its holdings in AnaptysBio by 105.6% in the fourth quarter. Tema Etfs LLC now owns 22,560 shares of the biotechnology company’s stock valued at $1,094,000 after acquiring an additional 11,585 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of AnaptysBio by 56.0% in the fourth quarter. BNP Paribas Financial Markets now owns 164,823 shares of the biotechnology company’s stock valued at $7,991,000 after buying an additional 59,160 shares in the last quarter.

Insider Transactions at AnaptysBio

In related news, Director John P. Schmid sold 20,645 shares of AnaptysBio stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $56.11, for a total transaction of $1,158,390.95. Following the completion of the sale, the director owned 31,622 shares of the company’s stock, valued at $1,774,310.42. The trade was a 39.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Daniel Faga sold 17,679 shares of AnaptysBio stock in a transaction dated Friday, March 27th. The stock was sold at an average price of $61.61, for a total value of $1,089,203.19. Following the sale, the chief executive officer directly owned 495,965 shares of the company’s stock, valued at $30,556,403.65. This trade represents a 3.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 33.50% of the company’s stock.

AnaptysBio announced that its board has approved a share buyback plan on Friday, March 27th that allows the company to repurchase $100,000.00 billion in shares. This repurchase authorization allows the biotechnology company to repurchase up to 5,352,316.2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.